Clinical trials: Rejection Chronic Renal
Rejection Chronic Renal, Kidney Transplant Rejection
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
Our group recently reported that tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, may be effective when administered monthly to patients with chronic antibody-mediated rejection (ABMR).
- Trial name
- NCT03859388
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cedars-Sinai Medical Center
Kidney Transplantation, Vitamin D Deficiency
Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients
The purpose of the study is to evaluate the effects of Cholecalciferol (Vitamin D3) substitution on the posttransplant outcome (glomerular filtration rate as well as serum creatinine levels, number of acute rejection episodes…
- Conditions
- Kidney Transplantation, Vitamin D Deficiency, Renal Osteodystrophy
- Trial name
- VITA-D (NCT00752401)
- Testing
- Cholecalciferol
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Kidney Transplant Failure and Rejection
AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
This is a prospective cohort observational study to assess the role of AlloSure Donor Derived Cell Free DNA (ddcfDNA) assay in the monitoring of three high-risk groups of kidney transplant patients for antibody mediated…
- Trial name
- All-MAP (NCT04057742)
- Testing
- AlloSure ddcfDNA assay, AlloMap assay, Inflammatory Cytokines
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Wisconsin, Madison
Kidney Disease, End-Stage, Donor Specific Antibodies
Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
In spite of conventional immunosuppression with lymphocyte-depleting induction followed by tacrolimus- and mycophenolate-based regimens, African American (AA) renal transplant recipients experience higher rates of acute rejection…
- Conditions
- Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant
- Trial name
- NCT04665310
- Testing
- Envarsus XR
- Volunteers
- 46 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Transplantation
The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation
This study will examine whether measurements of connective tissue growth factor (CTGF) and other cell proteins can identify which kidney transplant recipients are likely to develop chronic allograft nephropathy (CAN), a disease…
- Trial name
- NCT00056784
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End-stage Renal Failure, Graft Rejection
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
The current anti-rejection drug regime for kidney transplant recipients in use at the West London Renal \& Transplant Centre (WLRaTC) consists of induction therapy with the very potent monoclonal antibody Campath 1-H…
- Trial name
- TAESR (NCT00807144)
- Testing
- Tacrolimus (Kidney transplant maintenance immunosuppression), Kidney transplant maintenance immunosuppression
- Where
- United Kingdom
- Volunteers
- 102 people
- Sponsor
- Imperial College Healthcare NHS Trust
Antibody-mediated Rejection in Kidney Transplant
Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection
This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR
- Trial name
- NCT05452317
- Testing
- Chronic active AMR group, Non-Chronic active AMR group
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- CSL Behring
End-stage Renal Failure, Kidney Graft Rejection
Reference Group Trial for The ONE Study
To investigate the progression of the immunological response in living-donor kidney transplant recipients treated with a standard immunosuppressive regimen.
- Trial name
- NCT01656135
- Testing
- Blood drawing for immune monitoring and questionnaires
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- University of Regensburg
Solid Organ Transplant Rejection, Chronic Kidney Failure
Exercise Training and Kidney Transplantation
The goal of this clinical trial is to investigate the physiological and molecular effects of exercise training in transplant recipients. The main questions it aims to answer are: 1.
- Conditions
- Solid Organ Transplant Rejection, Chronic Kidney Failure, Quality of Life, Inflammation
- Trial name
- EXTRA (NCT06216015)
- Testing
- Exercise training, Continue exercising, Discontinue exercising
- Volunteers
- 345 people
- Sponsor
- Hugo de Luca Correa
Kidney Injury, Kidney Failure
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs, underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure.
- Conditions
- Kidney Injury, Kidney Failure, Kidney Failure, Chronic, Kidney Failure, Acute
- Trial name
- STAART (NCT05747053)
- Testing
- AlloSure, PAXGene
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- George Washington University
End-Stage Renal Disease, Kidney Failure
Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
T regulatory cells (T regs) are responsible for immune tolerance in solid organ transplant patients. This study will evaluate the treatment of children with kidney transplants either with Campath and other immune system…
- Trial name
- NCT01446484
- Testing
- CD4+CD25+CD127lowFoxP3+ T regulatory cells injection, Alemtuzumab, Mycophenolate mofetil
- Where
- 2 sites in Russia
- Volunteers
- 30 people
- Sponsor
- Pirogov Russian National Research Medical University
Graft Rejection, Kidney Transplantation
A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
A study to compare the conversion to Prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure
- Trial name
- CRAF (NCT00510913)
- Testing
- tacrolimus
- Where
- 18 sites in United States
- Volunteers
- 450 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplant Rejection
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR).
- Trial name
- NCT07006532
- Testing
- Tocilizumab
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
End Stage Kidney Disease, Immunological Tolerance
Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants
The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function…
- Conditions
- End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Trial name
- NCT05525507
- Testing
- Conditioning and Stem cell infusion
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences
End-stage Renal Disease
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation
Chronic renal failure is a major public health problem in industrialized countries, due to its frequency - about 3 million patients in France - and its socio-economic impact.
- Trial name
- ECLAT (NCT03994497)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Angers
Kidney Diseases, Kidney Transplant
TreaT-Assay: the New Frontier for the Diagnosis of Acute Rejection in Kidney Transplantation
Kidney transplantation is the standard therapy for end-stage renal disease. Acute rejection (AR) or chronic rejection along with reactive donor immunity, which counteracts organ acceptance, are among the greatest medical…
- Conditions
- Kidney Diseases, Kidney Transplant, Kidney Disease, End-Stage
- Trial name
- NCT06801262
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN)
Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients
Chronic Allograft Nephropathy (CAN)/Interstitial fibrosis and Tubular Atrophy (IFTA) is responsible for most kidney transplant failures. CAN/IFTA on a 3 month kidney biopsy strongly predicts graft survival long term.
- Conditions
- Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
- Trial name
- Mini-Kidney (NCT01531257)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Grafting, Renal Transplantation
Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
To evaluate the benefit of rituximab in patients with CAN with histologically proven C4d deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts.
- Conditions
- Grafting, Renal Transplantation, Transplantation, Kidney, Chronic Allograft Nephropathy
- Trial name
- Rituximab 2006 (NCT00568477)
- Testing
- MabThera
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Technical University of Munich
End Stage Renal Disease, Rejection of Renal Transplant
Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
The overall aim of the study is to prospectively investigate the impact of two maintenance calcineurin inhibitor immunosuppressive regimens: once-daily extended release tacrolimus and twice-daily tacrolimus on subpopulations of T…
- Trial name
- NCT03289650
- Testing
- Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Lorenzo Gallon